Screening for Polymyalgia Rheumatica
Routine screening for polymyalgia rheumatica in asymptomatic adults, including those over 65 years old, is not recommended and has no role in clinical practice.
Why Screening Is Not Indicated
PMR is a clinical diagnosis that requires the presence of characteristic symptoms—specifically bilateral shoulder and hip girdle pain with prolonged morning stiffness in patients over 50 years of age 1, 2. The disease cannot be diagnosed through laboratory markers alone, as there is no specific diagnostic test for PMR 2, 3.
The 2015 EULAR/ACR guidelines explicitly address management of patients with clinician-diagnosed PMR or those meeting classification criteria, but make no mention of screening asymptomatic individuals 1. This omission is deliberate—PMR is fundamentally a symptomatic condition where:
- Diagnosis depends on clinical presentation, not laboratory abnormalities
- Elevated inflammatory markers (ESR/CRP) are common but non-specific
- Treatment with glucocorticoids carries significant risks that outweigh any theoretical benefit in asymptomatic individuals
The Case-Finding Approach Instead
Rather than screening, the guidelines emphasize rapid specialist referral when PMR is suspected based on symptoms 1, 4. The appropriate clinical pathway is:
When to Consider PMR (Symptomatic Patients Only):
- Age >50 years (typically >65 years)
- Bilateral shoulder and hip girdle pain
- Morning stiffness >45 minutes
- Elevated inflammatory markers (though normal ESR does not exclude PMR 5)
- Rapid response to low-dose glucocorticoids (diagnostic clue)
Immediate Actions for Suspected Cases:
- Document minimal clinical and laboratory dataset before starting treatment 1
- Assess for atypical features requiring urgent specialist referral: peripheral inflammatory arthritis, systemic symptoms, low inflammatory markers, age <60 years 1
- Evaluate comorbidities that increase glucocorticoid-related risks 1
Why Universal Vascular Ultrasound Screening Is Also Not Recommended
Recent debate has emerged about whether all PMR patients should undergo vascular ultrasound to detect subclinical giant cell arteritis. This approach is not supported by current evidence 6. A 2025 analysis argues that universal vascular ultrasound screening in PMR is "speculative" and resources should instead address misdiagnosis and glucocorticoid overtreatment 6.
The 1997 literature established that temporal artery biopsy is not indicated in patients with pure PMR symptoms without clinical features of giant cell arteritis 5.
Critical Pitfalls to Avoid
- Do not order inflammatory markers in asymptomatic elderly patients as a screening tool—this leads to false positives and unnecessary treatment
- Do not start glucocorticoids empirically without documented symptoms, as treatment carries substantial morbidity including osteoporosis, diabetes, ocular complications, and infection risk 6
- Do not confuse case-finding with screening—PMR diagnosis requires active symptoms, not just age and elevated ESR
The Harm of Inappropriate Screening
Glucocorticoid therapy, while effective for symptomatic PMR, causes adverse events in approximately 50% of patients 1. In the absence of symptoms, treatment provides no benefit while exposing patients to:
- Osteoporotic fractures
- Diabetes and glucose intolerance
- Cardiovascular complications
- Infections
- Weight gain and metabolic syndrome
The focus should remain on accurate diagnosis of symptomatic patients and timely specialist referral, not population-based screening 1, 4.